Bayer: Multiple Sclerosis trials

The registry lists 37 Multiple Sclerosis studies with Bayer as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 1Phase 2 2Phase 3 3Phase 4 3No phase 28(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple SclerosisCompletedNCT00370071Phase 3Results posted
• Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or RebifCompletedNCT00317941Phase 4Results posted
• BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up StudyCompletedNCT00185211Phase 3Results posted
• An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and SwedenActive, not recruitingNCT06053749
• US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT AutoinjectorCompletedNCT04356339
• PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With BetaferonCompletedNCT03808142
• Betaferon Use in Children and Adolescents With Multiple SclerosisCompletedNCT03577977
• Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1bCompletedNCT03408093
• BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up StudiesCompletedNCT03269175Phase 4
• Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot StudyCompletedNCT03134573
• EPID Multiple Sclerosis Pregnancy StudyCompletedNCT02749396
• Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With BetaferonCompletedNCT02486640
• BAY86-5046 (Betaseron), Non Interventional StudiesCompletedNCT02121444
• Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple SclerosisCompletedNCT01795872Phase 4
• Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on BetaferonCompletedNCT01766063
• Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)CompletedNCT01706055
• Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple SclerosisCompletedNCT01491100
• Betaferon® Regulatory Post-Marketing SurveillanceCompletedNCT01414816
• Depression and Fatigue in MS Patients Treated With Betaferon.CompletedNCT01354665
• Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectorsCompletedNCT01235455
• BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus ProgramCompletedNCT01233245
• Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple SclerosisCompletedNCT01184833
• Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years PeriodCompletedNCT01076595
• QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in KoreaWithdrawnNCT01071694
• Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.CompletedNCT01031459
• Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy VolunteersCompletedNCT01031199Phase 1
• Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple SclerosisCompletedNCT00963833
• Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis PatientsCompletedNCT00928967
• Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)CompletedNCT00902135
• BEYOND Pilot StudyCompletedNCT00893217Phase 2
• Physical Activity and Fatigue in Early Multiple Sclerosis (MS)CompletedNCT00882453
• Physical Disability in Patients Treated With BetaferonCompletedNCT00873340
• Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor OveractivityTerminatedNCT00845338Phase 2
• BENEFIT Extension StudyCompletedNCT00544037
• Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With BetaseronCompletedNCT00461396
• Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnNCT00313976Phase 3
• Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00206635